Compare Altria Group Inc (MO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Viatris Inc — how do they compare? Altria Group Inc trades at $74.53 (market cap $124.67B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Altria Group Inc is far larger — about 6.3× Viatris Inc's market cap, and Altria Group Inc pays the higher dividend (5.68%). Which is the better fit depends on your goals.
| MO | VTRS | |
|---|---|---|
Market Cap | $124.67B | $19.79B |
Sector | Consumer Staples | Health |
52-Week High | $74.66 | $17.39 |
52-Week Low | $54.72 | $8.74 |
Enterprise Value | $145.75B | $32.00B |
Dividend Yield | 5.68% | 2.83% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
